PubMed Health⌕ Search

Biomedical subjects

A I Vengerovskiĭ

Publications and source records attributed to A I Vengerovskiĭ.

At least 19 recordsLinked to original sources
PubMed2000

[Lochein - a novel hepatoprotective drug].

A trial of a novel hepatoprotective plant drug lochein (Salsola extract) developed in Russia was performed in 110 patients with a verified chronic hepatitis of viral (73 patients) or alcohol (36 patients) etiology versus well-known hepatoprotector corsil given to 40 patients. Lochein demonstrated more potent effect than corsil.

Adult↗
PubMed1987

[The effect of hepatoprotectors on lipid metabolism in CCl4-hepatitis].

The hepatoprotective agents, silybinin and essentiale, were shown to prevent the development of lipid metabolism disturbances in the liver and serum of rats with CCl4-hepatitis. Slow accumulation of triglycerides, lysophosphatidylcholine and cardiolipin was observed in animals treated with these drugs, while phosphatidylcholine liver level remained high. Silybinin and essentiale inhibited the production of lipid hydroperoxide, Shiff basis, malonic dialdehyde, intensified the function of tissue antioxidants, activated liver beta-hydroxybutyrate dehydrogenase and depressed the activation of serum phospholipase A.

Animals↗
PubMed1987

[Hepatotropic action of benzobamil in CCl4 poisoning].

The administration of an antiepileptic drug--benzobamilum-to rats with CCl4-induced hepatitis prevents the development of liver parenchyma necrosis, promotes the retention of normal enzyme activity in hepatocytes, stimulates the excretory and antitoxic liver functions. The drug has antioxidant properties, inhibits the production of lysophosphatidylcholine and the reduction in phosphatidylcholine content in the liver homogenates but fails to intensify CCl4-induced steatosis.

Animals↗
PubMed1977

[Structural and metabolic disorders in the heart, liver and kidneys in adjuvant disease].

Histochemical changes in the heart, liver and kidneys and ultrastructural disorders in cardiomyocytes were studied in 40 white rats with adjuvant disease. Mucoid lesions, hydropyc dystrophy and necribiosis of muscle cells developed in the heart, diffuse extra-intracapillary glomerulonephritis in combination with nephrosis in the kidneys. In the liver, dyscomplexation of hepatic trabeculas, distention of perisinusoidal spaces were observed; in hepatocytes, the processes of protein synthesis were activated, and signs of hydropyc dystrophy and necrobiosis developed. The activity of enzymes of the aerobic phase of energetic metabolism was reduced and that of lactate dehydrogenase and acid phosphatase increased in cardiomyocytes, hepatocytes, and epithelium of convoluted tubules of the kidneys. Mitochondria of cardiomyocytes were swollen, myofibrilles fragmented.

Animals↗
PubMedDate not supplied

[The joint use of prednisolone and phospholipid-containing hepatoprotectors in experimental chronic hepatitis].

In chronic CCl4-hepatitis in rats phospholipid-containing hepatoprotectors, essentiale and eplir differ in their influence on the therapeutic effect of prednisolone; essentiale does not change the antiproliferative effect of the glucocorticoid and weakens its membrane-stabilizing effect, eplir increases these therapeutic effects of prednisolone. Besides, eplir, in distinction from essentiale, reduces lipid accumulation in the liver and hypoproteinemia which are induced by prednisolone.

Animals↗
PubMedDate not supplied

[Reye's syndrome--a severe complication of salicylate therapy].

Clinical and experimental data are reviewed on the Reye's syndrome--a heavy complication accompanying the therapy of viral infections in children by salicylates. Disorders in the bioenergetics of fatty acid oxidation and ammonia utilization are considered in the context of clinical manifestations of the Reye's syndrome.

Acute Disease↗
PubMedDate not supplied

[Effect of ammonium succinate on pharmacological effects of acetylsalicylic acid].

Ammonia succinate potentiates the main pharmacological properties and reduces the toxic effects (ulcerogenic action and general toxicity) of acetylsalicylic acid. The new preparation astam, representing a combination of acetylsalicylic acid with ammonia succinate in a 2:1 ratio, is proposed. Astam exhibits antiexudative, capillary-reinforcing, antiproliferative, pain-relieving, antipyretic, antiaggregant, and antioxidant properties. In addition, the drug inhibits the development of structural-metabolic disorders in the case of chronic immune inflammation of joints and various internal organs.

Animals↗
PubMedDate not supplied

[Therapeutic effect of hepatoprotectors in experimental Reye syndrome].

Maxar and legalon--hepatoprotectors containing polyphenols--exhibit a therapeutic effect with respect to the experimental Reye's syndrome induced in rats by intraperitoneal injections of 4-pentenoic acid. Maxar restores the activity of enzymes of the hepatic origin, normalizes the content of bilirubin, glucose, phenols, and malonic aldehyde in the blood serum, stimulates the production of ketone bodies and ammonia detoxication, and improves the histologic structures of liver and cortex. Legalon also decreases the structural-metabolic disorders accompanying the Reye's syndrome, but to as lower ewxtent.

Animals↗
PubMedDate not supplied

[Enteric sorbents potentiate hepatoprotective effect of eplir in experimental toxic hepatitis].

The administration of eplir (a phospholipid-containing hepatoprotector), as well as of the enterosorbents polyphepan and EST-1 (an agent obtained from dry peat extract), to rats with tetrachloromethane-induced hepatitis protect the liver parenchyma against dystrophy, necrosis, and inflammation, reduce hyperfermentemia, decrease the blood bilirubin, ammonia, phenols, and malonaldehyde, and increase the urea content in blood serum, while not fully restoring all these biochemical parameters on the normal level. The treatment of rats with toxic hepatitis by a combination of eplir and enterosorbents is accompanied by a synergistic increase in the therapeutic efficacy of each component, leading to normalization of the biochemical parameters reflecting the functional slate of liver.

Animals↗
PubMedDate not supplied

[Hepatoprotective properties of liproxol].

The experiments on rats with a model toxic liver damage (tetrachloromethane hepatitis) showed evidence of a high hepatoprotector activity of liproxol, representing a combination of eplir and lokhein mixed in a 1-12 ratio. Liproxol inhibits lipid peroxidation, stimulates the excretory and detoxicant functions of liver, reduces hyperfermentation, and normalized membrane phospholipid composition.

Animals↗
PubMedDate not supplied

[Efficacy of enzyme-inducing agents in experimental tetrachloromethane poisoning].

Liver monooxygenase system inductors benzonal, galonal, and galodif exceed phenobarbital and zixorin in therapeutic efficacy with respect to rats poisoned with tetrachloromethane. The former drugs increase the content and catalytic activity of cytochrome P-450, improve conjugation with reduced glutathione, prevent the cytolysis of hepatocytes, and stimulate the bile secretion and the liver excretion function.

Animals↗
PubMedDate not supplied

[The effect of hepatoprotectors containing phospholipids on rats with experimental acute pancreatitis].

The experiments on rats with a model acute pancreatitis showed that hepatoprotectors containing phospholipids (eplir and essentiale) improve the parameters of metabolism and the functions and histological characteristics of the pancreas and liver. Both drugs produced an antioxidant effect, decreased the activity of alpha-amylase, lipase, enzymes of hepatic origin in the blood, and reduced the content of creatinine, glucose, urea, bilirubin, and lipids. The therapeutic action of eplir was more pronounced than that of essentiale.

Acute Disease↗
PubMedDate not supplied

[Hepatoprotectors containing phospholipids decrease the immunosuppressive effect of prednisolone in rats with experimental toxic hepatitis].

The experiments on rats with a model toxic hepatitis induced by tetrachloromethane showed that hepatoprotectors containing phospholipids (eplir and essentiale) introduced in combination with prednisolone decrease the immunodepressant effect of this glucocorticoid, as manifested by a decrease in the atrophy of thymus and an increase in the amount of blood lymphocytes, the number of splenic blasts, and the functional activity of mononuclear cells in C3b and Fc(gamma) receptors in peritoneal exudate.

Animals↗